Showing results (51-60 of 146) with videos related to

Sort By:
Pageof 15
Human Gene Therapy|October 13, 2005
Product-enhanced reverse transcriptase assay for replication-competent retrovirus and lentivirus detectionLakshmi Sastry, Yi Xu, Lisa Duffy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignanciesMichael J Robertson, David Pelloso, Rafat Abonour, et al.
Expert Review of Hematology|February 4, 2010
Novel targeted drug therapies for the treatment of childhood acute leukemiaPatrick Brown, Stephen P Hunger, Franklin O Smith, et al.
Human Gene Therapy Methods|January 31, 2013
Vector production in an academic environment: a tool to assess production costsAaron Boeke, Patrick Doumas, Lilith Reeves, et al.
BMC Palliative Care|April 11, 2024
Impact of training on knowledge, confidence and attitude amongst community health volunteers in the provision of community-based palliative care in rural KenyaHussein Elias, Evelyne Kisembe, Sarah Nyariki, et al.
Leukemia Research|February 13, 2002
Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levelsSima Jeha, Franklin O Smith, Elihu Estey, et al.
Human Gene Therapy|September 22, 2011
Efficient large volume lentiviral vector production using flow electroporationScott R Witting, Lin-Hong Li, Aparna Jasti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 24, 2010
Replication-competent lentivirus analysis of clinical grade vector productsKenneth Cornetta, Jing Yao, Aparna Jasti, et al.
Stem Cells (Dayton, Ohio)|December 2, 2006
Enhanced green fluorescent protein is a nearly ideal long-term expression tracer for hematopoietic stem cells, whereas DsRed-express fluorescent protein is notWen Tao, Barbara-Graham Evans, Jing Yao, et al.
Cytotherapy|July 28, 2020
Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapiesMichael Scott, Dominic Clarke, Yonatan Lipsitz, et al.
Pageof 15